Mads Ravnborg

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

Vittorio Martinelli, M. Rodegher, Lucia Moiola et al. · The Lancet · 2009 · 585 citations

Neurological Disorder, Medicine, Clinical Neurology +8

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Per Soelberg Sørensen, Katja Maria Clemmesen, Klaus Bendtzen et al. · The Lancet · 2003 · 371 citations

Clinical Immunology, Relapsing-remitting Multiple Sclerosis, Autoimmune Disease +12

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Ludwig Kappos, David O. Bates, Gilles Edan et al. · The Lancet Neurology · 2011 · 265 citations · Full text

Translational Medicine, Systemic Scleroderma, Medicine +9

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

B. Wanscher, C.V. Jensen, Karen Schreiber et al. · Neurology · 1998 · 239 citations

Neurological Disorder, Immunology, Clinical Neurology +22